Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care.

Am J Respir Crit Care Med

4 Thorax Institute, Hospital Clinic in Barcelona, University of Barcelona, Barcelona, Spain.

Published: December 2016

Chronic obstructive pulmonary disease (COPD) is a global health issue with high social and economic costs. Concomitant chronic cardiac disorders are frequent in patients with COPD, likely owing to shared risk factors (e.g., aging, cigarette smoke, inactivity, persistent low-grade pulmonary and systemic inflammation) and add to the overall morbidity and mortality of patients with COPD. The prevalence and incidence of cardiac comorbidities are higher in patients with COPD than in matched control subjects, although estimates of prevalence vary widely. Furthermore, cardiac diseases contribute to disease severity in patients with COPD, being a common cause of hospitalization and a frequent cause of death. The differential diagnosis may be challenging, especially in older and smoking subjects complaining of unspecific symptoms, such as dyspnea and fatigue. The therapeutic management of patients with cardiac and pulmonary comorbidities may be similarly challenging: bronchodilators may have cardiac side effects, and, vice versa, some cardiac medications should be used with caution in patients with lung disease. The aim of this review is to summarize the evidence of the relationship between COPD and the three most frequent and important cardiac comorbidities in patients with COPD: ischemic heart disease, heart failure, and atrial fibrillation. We have chosen a practical approach, first summarizing relevant epidemiological and clinical data, then discussing the diagnostic and screening procedures, and finally evaluating the impact of lung-heart comorbidities on the therapeutic management of patients with COPD and heart diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1164/rccm.201604-0690SODOI Listing

Publication Analysis

Top Keywords

patients copd
24
chronic obstructive
8
obstructive pulmonary
8
pulmonary disease
8
cardiac
8
cardiac diseases
8
copd
8
patients
8
cardiac comorbidities
8
therapeutic management
8

Similar Publications

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide and greatly reduces the quality of life. Utilizing remote monitoring has been shown to improve quality of life and reduce exacerbations, but remains an ongoing area of research. We introduce a novel method for estimating changes in ease of breathing for COPD patients, using obstructed breathing data collected via wearables.

View Article and Find Full Text PDF

Introduction: Little is known about the effectiveness and safety of oxygen saturation (SpO2) thresholds in children admitted with respiratory distress. The current 90%-94% threshold could lead to prolonged administration of supplemental oxygen, increased duration of hospital admissions, distress for children and families, and healthcare costs. To balance reducing unnecessary oxygen administration and preventing hypoxia, a lower SpO2 threshold of 88% for oxygen supplementation in children has been suggested.

View Article and Find Full Text PDF

Chronic obstructive pulmonary disease (COPD) is a common condition that complicates major surgeries like coronary artery bypass grafting (CABG). This study aims to evaluate the impact of COPD on the outcome of CABG. A registry-based retrospective cohort study included individuals who received CABG between 2009 and 2016.

View Article and Find Full Text PDF

Background: Some patients with severe asthma have overlapping allergic and eosinophilic phenotypes and may be eligible for anti-eosinophilic or anti-IgE biologics.

Objective: This post hoc sub-analysis assessed real-world mepolizumab effectiveness in patients with overlapping allergic and eosinophilic phenotypes, using 1-year data from the international, prospective REALITI-A study.

Methods: The clinically significant asthma exacerbation (CSE) rate was assessed 1 year prior to (pre-treatment) and following (follow-up) mepolizumab treatment, stratified by baseline total IgE levels (tIgE; <60, 60-<190, 190-<550, and ≥550 kU/L), atopic status (yes/no/unknown), prior omalizumab use (yes/no), geographic baseline omalizumab eligibility (eligible/non-eligible), and baseline tIgE level and blood eosinophil count (BEC) threshold combinations (<81 or ≥81 kU/L and <300 or ≥300 cells/µL).

View Article and Find Full Text PDF

Baseline characteristics of patients in the Chinese Bronchiectasis Registry (BE-China): a multicentre prospective cohort study.

Lancet Respir Med

January 2025

Division of Respiratory Medicine and Gastroenterology, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. Electronic address:

Background: Bronchiectasis is a disease with a global impact, but most published data come from high-income countries. We aimed to describe the clinical characteristics of patients with bronchiectasis in China.

Methods: The Chinese Bronchiectasis Registry (BE-China) is a prospective, observational cohort enrolling patients from 111 hospitals in China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!